Acute Monoblastic Leukemia (AmoL)
Symptoms, Doctors, Treatments, Advances & More

Acute Monoblastic Leukemia (AmoL) Overview

Save information for later
Sign Up

Learn About Acute Monoblastic Leukemia (AmoL)

View Main Condition: Leukemia

What is the definition of Acute Monoblastic Leukemia (AmoL)?
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
What are the alternative names for Acute Monoblastic Leukemia (AmoL)?
  • Acute monoblastic leukemia
  • AML M5
  • AML-M5
  • Acute monocytic leukemia
  • Acute myeloblastic leukemia type 5
Who are the top Acute Monoblastic Leukemia (AmoL) Local Doctors?
Elite in Acute Monoblastic Leukemia (AmoL)
Elite in Acute Monoblastic Leukemia (AmoL)
Referral may be required

University Of Colorado Hospital

12605 E 16th Ave, 
Aurora, CO 
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Pollyea is a Hematologist practicing medicine in Aurora, Colorado. Dr. Pollyea is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Pollyea is currently accepting new patients.

Elite in Acute Monoblastic Leukemia (AmoL)
Elite in Acute Monoblastic Leukemia (AmoL)
Referral may be required

Montefiore Medical Park At Eastchester

1695 Eastchester Road, 
Bronx, NY 
718-405-8504
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marina Konopleva is a Hematologist practicing medicine in Bronx, New York. Dr. Konopleva is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). She is also highly rated in 25 other conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Konopleva is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Monoblastic Leukemia (AmoL)
Elite in Acute Monoblastic Leukemia (AmoL)
Referral may be required
157 Xiwu Road, 
Xi'an, CN 

Wanggang Zhang practices practicing medicine in Xi'an, China. Zhang is rated as an Elite expert by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). They are also highly rated in 3 other conditions, according to our data. Their clinical expertise encompasses Acute Monoblastic Leukemia (AmoL), Acute Myeloid Leukemia (AML), Leukemia, and Multiple Myeloma.

View All Doctors
What are the latest Acute Monoblastic Leukemia (AmoL) Clinical Trials?
A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine Alternating With Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 2

Summary: This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein neede...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Venetoclax Combined With CACAG Regimen Versus 3+7 Regimen in the Treatment of Acute Monocytic Leukemia: A Prospective, Randomized, Controlled Study
Venetoclax Combined With CACAG Regimen Versus 3+7 Regimen in the Treatment of Acute Monocytic Leukemia: A Prospective, Randomized, Controlled Study
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center